NERLYNX is a kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed\/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.<\/p>\n
Nerlynx (neratinib tablets) for oral use Initial U.S. Approval:\u00a0 2017
\nTo access neratinib tablets sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN’s Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj)<\/p>\n","protected":false},"excerpt":{"rendered":"
Nerlynx (neratinib) is a medication indicated for the adjuvant treatment of adult patients with early-stage HER2 positive overexpressed\/amplified breast cancer.<\/p>\n
Disease Indications-Breast Cancer If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import \u201cNeratinib Tablets\u201d based on the information you provide.<\/strong><\/p>\n
\nManufacturer-Puma biotechnology
\nUsage-Intravenous
\nMedicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA)\u00a0Health Canada, Therapeutic Goods Administration (TGA)
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n